Laboratory of Immunoregulation, National Institutes of Health, Bethesda, MD, USA.
J Infect Dis. 2011 Jul 1;204(1):135-8. doi: 10.1093/infdis/jir208.
Residual plasma viremia (<50 copies/mL) persists in certain human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART); however, the relationship between the degree of residual plasma viremia, the size of HIV reservoirs, and the level of immune activation has not been delineated. Here, we demonstrate that residual plasma viremia correlates with the size of the CD4(+) T cell viral reservoir, but not with markers of immune activation, suggesting that reactivation of the latent viral reservoir may not be the sole source of residual plasma viremia. Novel therapeutic strategies aimed at targeting the source of residual viremia may be necessary to achieve viral eradication.
在接受抗逆转录病毒治疗 (ART) 的某些人类免疫缺陷病毒 (HIV) 感染者中,仍存在残余血浆病毒血症(<50 拷贝/毫升);然而,残余血浆病毒血症的程度、HIV 储存库的大小以及免疫激活水平之间的关系尚未明确。在这里,我们证明残余血浆病毒血症与 CD4(+) T 细胞病毒储存库的大小相关,但与免疫激活标志物无关,这表明潜伏病毒储存库的重新激活可能不是残余血浆病毒血症的唯一来源。可能需要针对残余病毒血症来源的新型治疗策略来实现病毒清除。